Hoseinpour, RasoulHasani, AlkaBaradaran, BehzadAbdolalizadeh, JalalSalehi, RoyaHasani, AkbarMemar, Mohammad Yousef2024-05-252024-05-25202402405-844010.1016/j.heliyon.2024.e261932-s2.0-85185467092https://doi.org/10.1016/j.heliyon.2024.e26193https://hdl.handle.net/20.500.14517/1200Despite the widespread use of the Bacillus Calmette-Gue ' rin (BCG) vaccine, Mycobacterium tuberculosis (MTB) continues to be a global burden. Vaccination has been proposed to prevent and treat tuberculosis (TB) infection, and several of them are in different phases of clinical trials. Though vaccine production is in progress but requires more attention. There are several TB vaccines in the trial phase, most of which are based on a combination of proteins/adjuvants or recombinant viral vectors used for selected MTB antigens. In this review, we attempted to discuss different types of TB vaccines based on the vaccine composition, the immune responses generated, and their clinical trial phases. Furthermore, we have briefly overviewed the effective delivery systems used for the TB vaccine and their effectiveness in different vaccines.eninfo:eu-repo/semantics/openAccessTuberculosisVaccineDelivery systemsBacillusCalmette-GuerinReviewQ2Q1104WOS:00120004110000138404880